A gene therapy designed to block the activity of SARM1 protein prevented the loss of axons — long projections that connect…
Articles by Patricia Inácio, PhD
Amyotrophic lateral sclerosis (ALS) patients who complete the ongoing Phase 3 REFALS clinical trial evaluating levosimendan (also known as ODM-109)…
The loss of a key enzyme, called adenosine deaminase, in astrocytes — the energy-supporting cells of neurons — leads to…
SIRION Biotech and Denali Therapeutics have signed a new licensing agreement to develop a new generation of adeno-associated…
An upcoming webinar will focus on the novel approach to clinical trial design in the Modifying Immune Response and Outcomes…
MediciNova’s investigational therapy ibudilast (MN-166) combined with Rilutek (riluzole), for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, has been given…
Harvard neuroscientists have discovered how the TDP-43 protein — previously linked to sporadic and inherited amyotrophic lateral sclerosis (ALS) cases —…
The rate of weight loss from onset to diagnosis can be a significant indicator of poorer outcomes among amyotrophic…
A new method called Axon-seq allows researchers to analyze the content of messenger RNAs (mRNAs) in the motor neuron’s axons,…
Researchers have developed a new small molecule that targets the most common genetic defect behind amyotrophic lateral sclerosis (ALS) and…